Altos Therapeutics

Takeda, Altos Therapeutics partner for the treatment of gastroparesis

Tuesday, July 5, 2016

Takeda Pharmaceutical and Altos Therapeutics have entered into a definitive agreement to further the development of Altos’ proprietary compound ATC-1906. Additionally, the agreement includes an exclusive option for Takeda to acquire Altos beginning on the date of the agreement and continuing for a period of time following the completion of ongoing phase I studies of ATC-1906. The parties envision future development of ATC-1906 for the treatment of gastroparesis (GP) and its symptoms.

[Read More]